Quadrature Capital Ltd Has $34.31 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Quadrature Capital Ltd cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 61,050 shares of the biopharmaceutical company’s stock after selling 9,399 shares during the period. Quadrature Capital Ltd’s holdings in Regeneron Pharmaceuticals were worth $34,306,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Dodge & Cox boosted its position in Regeneron Pharmaceuticals by 64.6% in the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock valued at $2,008,799,000 after buying an additional 1,502,198 shares in the last quarter. Norges Bank acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth $628,151,000. Invesco Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 38.0% during the third quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock worth $834,675,000 after buying an additional 408,649 shares in the last quarter. Loomis Sayles & Co. L P lifted its stake in shares of Regeneron Pharmaceuticals by 18.6% in the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after acquiring an additional 305,089 shares during the last quarter. Finally, Federated Hermes Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 491.2% in the 2nd quarter. Federated Hermes Inc. now owns 245,587 shares of the biopharmaceutical company’s stock valued at $128,933,000 after acquiring an additional 204,045 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares in the company, valued at $13,860,169.59. The trade was a 0.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 5,274 shares of company stock worth $4,142,738 over the last 90 days. Company insiders own 7.02% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Evercore lifted their price target on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research note on Thursday, January 22nd. HSBC initiated coverage on Regeneron Pharmaceuticals in a research note on Monday, November 24th. They issued a “buy” rating and a $255.00 price objective for the company. JPMorgan Chase & Co. lifted their target price on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Morgan Stanley boosted their target price on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. Finally, Cantor Fitzgerald upped their price target on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $802.27.

Regeneron Pharmaceuticals Stock Down 3.6%

Shares of Regeneron Pharmaceuticals stock opened at $746.61 on Friday. The stock’s 50-day moving average is $770.34 and its 200 day moving average is $692.97. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The firm has a market cap of $78.93 billion, a price-to-earnings ratio of 17.96, a PEG ratio of 2.08 and a beta of 0.41. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. Regeneron Pharmaceuticals’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $12.07 EPS. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a dividend of $0.94 per share. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.05%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.